Scientists recreate blood-brain barrier on a chipScientists in Israel and the US have duplicated the blood-brain barrier in a chip using human stem cells, Share XScientists recreate blood-brain barrier on a chiphttps://pharmaphorum.com/news/scientists-recreate-blood-brain-barrier-on-a-chip/
J&J unveils top pipeline prospects, with main focus on cancerJohnson & Johnson has shone the spotlight on the most promising drugs in its pipeline, saying it plans Share XJ&J unveils top pipeline prospects, with main focus on cancerhttps://pharmaphorum.com/news/jj-unveils-top-pipeline-prospects-cancer/
German Merck shows new data backing BTK drug evobrutinib in MSGermany’s Merck KGaA has announced new mid-stage data that it says support further studies into its BTK inhibitor Share XGerman Merck shows new data backing BTK drug evobrutinib in MShttps://pharmaphorum.com/news/german-merck-shows-new-data-backing-btk-drug-evobrutinib-in-ms/
NICE backs Ocrevus for PPMS in England – but with caveatsPatients with a severe progressive form of multiple sclerosis will get access to the first licensed treatment for Share XNICE backs Ocrevus for PPMS in England – but with caveatshttps://pharmaphorum.com/news/nice-backs-ocrevus-for-ppms-in-england-but-with-caveats/
Biogen’s R&D strategy fails to impress after Alzheimer’s trial flopThe dust has settled at Biogen following the company’s disastrous announcement that it was ending development of Alzheimer’s Share XBiogen’s R&D strategy fails to impress after Alzheimer’s trial flophttps://pharmaphorum.com/news/biogens-rd-strategy-fails-to-impress-after-alzheimers-trial-flop/
Alder gears up for migraine showdown with eptinezumab filingAlder BioPharmaceuticals has filed its migraine drug eptinezumab with the US regulator, the last in a gang of Share XAlder gears up for migraine showdown with eptinezumab filinghttps://pharmaphorum.com/news/alder-gears-up-for-migraine-showdown-with-eptinezumab-filing/
European regulator restricts use of Sanofi MS drug LemtradaThe European drug regulator has called for a review of Sanofi’s multiple sclerosis drug Lemtrada following reports of Share XEuropean regulator restricts use of Sanofi MS drug Lemtradahttps://pharmaphorum.com/news/european-regulator-restricts-use-of-sanofi-ms-drug-lemtrada/
Novartis sues as Amgen tries to cancel migraine tie-upNovartis and Amgen have become embroiled in a legal row over rights to the migraine prevention drug Aimovig, Share XNovartis sues as Amgen tries to cancel migraine tie-uphttps://pharmaphorum.com/news/novartis-sues-as-amgen-tries-to-cancel-migraine-tie-up/
Teva’s migraine drug Ajovy approved in EuropeTeva’s migraine drug Ajovy (fremanezumab) has been approved in Europe, taking on rivals from the same class from Share XTeva’s migraine drug Ajovy approved in Europehttps://pharmaphorum.com/news/tevas-migraine-drug-ajovy-approved-in-europe/
